Equillium Stock

Equillium EBIT

The EBIT of Equillium (EQ) as of Jul 31, 2026 is -23.63 M USD. In the previous year, EBIT was -8.27 M USD — a change of 185.81% (lower).

EBIT

-23.63 MUSD

YoY

185.81%

Last updated:

In 2026, Equillium's EBIT was -23.63 M USD, a 185.81% increase from the -8.27 M USD EBIT recorded in the previous year.

The Equillium EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (undefined USD)
Date
EBIT (undefined USD)
Jan 1, 2023
0.00 base
Jan 1, 2024
0.00 base
Jan 1, 2025
0.00 base
Jan 1, 2026 (e)
0.00 base
Jan 1, 2027 (e)
0.00 base
Jan 1, 2028 (e)
0.00 base
Jan 1, 2029 (e)
0.00 base
Jan 1, 2030 (e)
0.00 base
YEAREBIT (undefined USD)
2030 est -
2029 est -
2028 est -
2027 est -
2026 est -
2025 -
2024 -
2023 -
2022 -
2021 -
2020 -
2019 -
2018 -
2017 -
Access this data via the Eulerpool API

Equillium Revenue

Equillium Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
36.08 M USD
-14.52 M USD
-13.34 M USD
Jan 1, 2024
41.10 M USD
-8.27 M USD
-8.07 M USD
Jan 1, 2025
130,000.00 USD
-23.63 M USD
-22.40 M USD
Jan 1, 2026 (e)
0.00 USD
-27.09 M USD
-14.70 M USD
Jan 1, 2027 (e)
0.00 USD
-32.29 M USD
-16.18 M USD
Jan 1, 2028 (e)
26.62 M USD
-31.11 M USD
-26.97 M USD
Jan 1, 2029 (e)
45.96 M USD
-36.98 M USD
-3.76 M USD
Jan 1, 2030 (e)
64.13 M USD
-46.76 M USD
32.61 M USD

Equillium Margins

Equillium stock margins

The Equillium margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Equillium. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Equillium.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
100.00 %
-40.24 %
-36.96 %
Jan 1, 2024
100.00 %
-20.12 %
-19.63 %
Jan 1, 2025
-89.23 %
-18,180.00 %
-17,229.23 %
Jan 1, 2026 (e)
-89.23 %
- %
- %
Jan 1, 2027 (e)
-89.23 %
- %
- %
Jan 1, 2028 (e)
-89.23 %
-116.85 %
-101.30 %
Jan 1, 2029 (e)
-89.23 %
-80.46 %
-8.19 %
Jan 1, 2030 (e)
-89.23 %
-72.92 %
50.86 %

Equillium Stock analysis

What does Equillium do? Equillium Inc is an emerging biotechnology company specializing in the research and development of therapies for the treatment of inflammatory and autoimmune diseases. The company was founded in 2017 by a group of experienced biotech entrepreneurs who aim to develop innovative and effective treatment methods to improve patients' quality of life. Equillium's business model focuses on the discovery and development of new therapies based on the modulation of the CD6 signaling pathway, a central regulator of the immune system. Equillium's technology aims to modulate the immune system to suppress an inflammatory response associated with autoimmune and other inflammatory diseases. The company collaborates closely with leading university research laboratories and experts in the field to develop effective therapies. Equillium targets a wide range of disease areas, including autoimmune diseases such as lupus, psoriasis, and Crohn's disease. The company has also developed a program to treat COVID-19, aiming to reduce the immune-mediated inflammatory response associated with severe cases of COVID-19. Equillium's product portfolio includes EQ001, a monoclonal antibody used for the treatment of lupus and other autoimmune diseases. EQ001 blocks the CD6 signaling pathway, thereby reducing inflammatory responses that attack healthy tissues in the body. The company is also working on developing a novel platform technology to explore additional therapy options based on the CD6 signaling pathway. Equillium has a strong funding base and is supported by some of the most renowned biotech investors. The company has a comprehensive pipeline of potential therapies that are intended to address a variety of indications in the future. Overall, Equillium's advanced biotechnological research and development have contributed to the discovery of new and effective ways to treat inflammatory and autoimmune diseases. The company is well-positioned to expand in this area of medicine and improve therapy options for patients worldwide. Equillium is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Equillium's EBIT

Equillium's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Equillium's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Equillium's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Equillium’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Equillium stock

EBIT of Equillium is -23.63 M USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Equillium

All Key Metrics — Equillium